Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Short term Debt (2016 - 2025)

Historic Short term Debt for Avalo Therapeutics (AVTX) over the last 8 years, with Q2 2025 value amounting to $370000.0.

  • Avalo Therapeutics' Short term Debt changed N/A to $370000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $370000.0, marking a year-over-year change of. This contributed to the annual value of $360000.0 for FY2024, which is N/A changed from last year.
  • Per Avalo Therapeutics' latest filing, its Short term Debt stood at $370000.0 for Q2 2025.
  • Avalo Therapeutics' Short term Debt's 5-year high stood at $370000.0 during Q2 2025, with a 5-year trough of $360000.0 in Q4 2024.